Welcome to our dedicated page for Dogwood Therapeutics SEC filings (Ticker: DWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dogwood Therapeutics filings document the regulatory record of a Delaware development-stage biopharmaceutical company focused on pain and neuropathy medicines. Its 8-K reports include financial results, Regulation FD shareholder letters, corporate updates, and material-event disclosures tied to the Halneuron® and SP16 IV development programs.
Proxy and meeting filings cover stockholder voting matters, governance, executive compensation, equity incentive plans, and Nasdaq-related approvals for warrant exercises and common stock issuances. The filing record also documents capital-structure matters, securities purchase agreements, equity awards, and risk-oriented disclosures associated with a clinical-stage biotechnology issuer.
Dogwood Therapeutics entered into an Exclusive Licensing Agreement with Serpin Pharma and Rejuvenation Labs granting Dogwood a royalty-free, sublicensable global license to develop Serpin's intravenous formulation of SP16, a first-in-class LRP1 agonist with reported anti-inflammatory and neural repair activity that may treat chemotherapy-induced peripheral neuropathy. As consideration, Dogwood agreed to issue 191,017 shares of common stock and 89.5939 shares of Series A-2 Non-Voting Convertible Preferred Stock to Serpin Pharma and the same amounts to Rejuvenation Labs. Tungsten received 10.8694 shares of Series A-2 Preferred Stock as advisor compensation. Related registration, support and voting agreements require Serpin, Tungsten-affiliated holders, and Sealbond to vote their shares in favor of proposals concerning potential issuances related to Series A, Series A-1 and Series A-2 conversions, certain equity plan matters, and possible adjournment of the meeting.